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Individuals who rely on public health payers to access new medicines can access
fewer innovative medicines and must wait longer in Canada compared to major markets
around the world. New medicines/indications approved by Health Canada and reviewed
for eligibility for reimbursement by the Common Drug Review or the pan-Canadian
Oncology Drug Review (CDR/pCODR) from the beginning of 2012 through to the
end of December 2016 were analyzed, with data taken from the relevant bodies’
websites and collected by IQVIA. This analysis investigated individual review segments –
Notice of Compliance (NOC) to Health Technology Assessment (HTA) submission,
HTA review time, pan-Canadian Pharmaceutical Alliance (pCPA) negotiation time, and
public reimbursement decision time, and analyzed the trends of each over time and
contributions to overall time to listing decisions. Average overall timelines for public
reimbursement after NOC were long and most of this time is taken up by HTA and
pCPA processes, at 236 and 273 days, respectively. This study confirms that Canadian
public reimbursement delays from 2013-2014 to 2015-2016 lengthened from NOC to
listing (Quebec + 53%, first provincial listing + 38%, and country-wide listing + 22%),
reaching 499, 505, and 571 days, respectively. Over the same period, time from NOC
to completion of HTA has increased by 33%, and time from post-HTA to first provincial
listing by 44%. The pCPA process appears to be the main contributor to this increasing
time trend, and although some provinces could be listing more quickly post-pCPA, they
appear to be listing fewer products. Reasons for large delays in time to listing include the
many-layered sequential process of reviews conducted before public drug plans decide
whether to provide access to new innovative medicines. Although there has been some
headway made in certain parts of the review processes (e.g., pre-NOC HTA), total time
to listing continues to increase, seemingly due to the pCPA process and other additional
review processes by drug plans. More clarity in the pCPA and provincial decision-making
processes and better coordination between HTA, pCPA, and provincial decision-making
processes is needed to increase predictability in the processes and reduce timelines for
Canadian patients and manufacturers.
Keywords: reimbursement, time to list, Canada, patient access to new medicines, CADTH, health
technology assessment
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INTRODUCTION
The publicly financed health insurance system in Canada covers
all Canadians for hospital and physician services for free at
the point of service, and is provided through federal, and
highly decentralized provincial and territorial plans (Marchildon,
2013). The Canadian health system is somewhat unique, in that
prescription medicines are not covered under Medicare unless
they are covered as part of a hospital-based service (as per the
Canada Health Act); thus Canada has developed its own unique
network of prescription drug coverage to meet the needs of its
population. As of January 1, 2018, 35.5 million Canadians are
eligible for some kind of drug coverage plan (representing 98% of
the Canadian population) (Dinh and Sutherland, 2017). Only two
other countries in the Organization for Economic Co-operation
and Development (OECD) have such a high private insurance
component of total healthcare spending: the United States and
Slovenia (OECD, 2017). Canada’s spending on pharmaceuticals
is comparable to the wealthiest OECD countries (ranked fifth
among 31 OECD countries in 2015 for expenditure per capita
on pharmaceuticals; US$685), as is its share of health care
spending (pharmaceuticals represent 14.4% of total healthcare
expenditure) (OECD, 2017).
The federal, provincial and territorial governments provide
drug plans that cover various populations. Although around
two-thirds of the population is estimated to be eligible to
be covered by a public drug program across the country,
based on eligibility criteria (Dinh and Sutherland, 2017), only
one-third of the Canadian population receives public drug
plan benefits (CIHI, 2017). The Federal Government funds
programs for First Nations and Inuit people, and other targeted
populations such as veterans and those under the auspices
of correctional services, the Canadian Forces, and the Royal
Canadian Mounted Police. Provincial and territorial public
drug plans likewise cover various specific populations and
each plan makes decisions about eligibility coverage criteria
and benefits. The majority of Canadians who are eligible for
these plans are seniors and low-income individuals and, in
certain provinces, other populations that may not have private
insurance – such as self-employed or working in trades with
limited or no private health benefits, or youth over 18 years
old that are not studying full-time. Some provinces have
Pharmacare (a monopolistic government-run public plan under
which everyone is eligible), however, most individuals do not
actually qualify to receive any reimbursement benefits because
their deductibles are set high compared to their actual drug
expenses in order to protect against catastrophic drug costs
(they would only pay minimal out-of-pocket expenses if they
Abbreviations: CADTH, Canadian Agency for Drugs and Technology in Health;
CDIAC, Cancer Drug Implementation Advisory Committee; CDR, Common
Drug Review; CEDAC, Canadian Expert Drug Advisory Committee; HTA, Health
Technology Assessment; INESSS, Institut national d’excellence en santé et en
services sociaux (National Institute for Excellence in Health and Social Services);
LOI, Letter of Intent; MSSS, Ministère de la Santé et des Services sociaux (Minister
of Health and Social Services); NOC, Notice of Compliance; NOCc, Notice of
Compliance with Conditions; pCODR, Pan-Canadian Oncology Drug Review;
pCPA, Pan-Canadian Pharmaceutical Alliance; PMPRB, Patented Medicine Prices
Review Board.
were also enrolled in a private plan that paid their deductible)
(Dinh and Sutherland, 2017). Forty-three percent (43%) of
prescription drug costs in Canada are paid by federal, provincial
and territorial public plans for all publicly covered populations
(CIHI, 2016).
Approximately 22.5 million (62% of Canadians) were covered
for prescription drugs by a private insurance plan in 2015 and
36% of Canada’s prescription drugs costs are covered by private
insurance (either employer-based or individual contracts) (CIHI,
2016). In most provinces, private drug plans are voluntary –
although private insurance is mandatory for eligible workers
in Quebec (Barnes and Anderson, 2015). The remainder of
prescription drug costs (22%) are estimated to be paid out-of-
pocket through deductibles or co-pays or by individuals who do
not actively participate in a prescription drug plan. In fact, the
Conference Board estimates that fewer than 1 million Canadians
(1.8% of the population) were not eligible for any insurance in
2018, and that an additional 3.6 million Canadians (10% of the
population) did not enroll in plans eligible to them in January
2018 (Dinh and Sutherland, 2017).
Health Canada is the federal government department
responsible for regulating the quality, safety and efficacy of
medicines in accordance with the Food and Drugs Act. If
the medicine under review meets safety, efficacy and quality
requirements, marketing authorisation may be granted and
either a NOC or NOC with conditions (NOC/c) is issued. The
medicine is then eligible to be reviewed for formulary listing and
reimbursement by both public and private plans. Each federal,
provincial and territorial public plan makes decisions about
coverage and establishes their own formularies. Formularies set
by private plans are generally more generous in terms of drug
coverage than public plans (Rovere and Skinner, 2016). Although
private plans do impose certain types of restrictions in terms of
criteria for reimbursement, 80% of private plans in Canada are
“open plans” without any exclusions in terms of their formularies
(TELUS Health, 2017).
Public plans have extensive review processes, relying heavily
on the HTA reviews conducted primarily from a public drug
plan perspective. In other words, the value of medicines is
evaluated in terms of health services and budgeting in the
context of public drug plans, whereas private payers place
greater emphasis on employee productivity, benefits packages,
and recruitment tools (Stewart, 2015; Sanofi, 2017). These
differences in review priorities may contribute to the fact that
private plans take a quarter of the time to add medicines to
their lists for reimbursement (4 months) compared to public
plans (16 months) (Rovere and Skinner, 2016). However, as the
utilization of medicines has increased and given that specialty
drugs for serious conditions are impacting their budgets, private
plans are turning to either their own economic evaluation
processes or to the public drug plans’ HTA process in search of
additional cost-containment measures (IQVIA, 2016).
In the past, many Canadian provincial governments
conducted their own clinical and economic evaluations to inform
decisions on medicine listing for their public programs. CADTH
is a third-party, government-funded HTA organization, created
the intergovernmental CDR in 2002. The CDR systematically
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assesses the comparative clinical effectiveness and the cost-
effectiveness of products with new active substances and all new
indications being requested for reimbursement. The purpose of
these assessments is to make more efficient recommendations on
specific reimbursement criteria and to enhance consistency in
decision making across different public drug plans managed at
the federal or provincial level for medicines provided outside of
a hospital setting (CADTH, 2016), which in Canada represents
about 89% of the total pharmaceutical market (IQVIA, 2016).
An alternative HTA review program was created in 2010,
initially called the “joint oncology drug review,” specializing in
oncology medicines used in hospital and retail settings (even
oncology medicines administered in hospital and palliative care
oncology medicines are reviewed). Later renamed pCODR, the
program makes recommendations to public drug plans and
provincial cancer agencies that make reimbursement decisions
for cancer medicines, specifically. pCODR’s remit is “to bring
consistency and clarity to the assessment of new cancer drugs,
by looking at both clinical evidence and cost-effectiveness”
(CADTH, 2018b).
In the province of Québec, INESSS conducts HTAs
and makes recommendations to the MSSS accordingly
(Québec, 2010).
When a manufacturer wishes a new product to be reimbursed
by public plans, it must send its submission to CADTH for
review by the CDR, or pCODR, or to INESSS for public
listing in Québec. After receiving an HTA recommendation
from the appropriate body, provincial, territorial and/or federal
plans may jointly negotiate with manufacturers through the
pCPA, but subsequently maintain the ability to make their
own decisions about inclusion of new products in their
formularies (i.e., decisions to list the product or not). Each
provincial plan makes reimbursement decisions on the basis
of their reviews of the cost-effectiveness and budget impact
of a new medicine and has the ability to further negotiate
prices with manufacturers thereafter. While public plans often
align with CADTH’s recommendations, enabling provincial
payers to consider their local context in their decision-making
illustrates the flexibility of the process (Allen et al., 2016). In
Québec, the Minister of Health makes decisions on coverage,
although there are stricter rules in place that are intended
to ensure that the Minister’s decisions are aligned with the
recommendations of INESSS.
The pCPA was established by the Council of Federation
(a collective of provincial and territorial premiers) in 2010
as a pan-Canadian body for the purpose of conducting
joint public drug plan negotiations for brand and generic
medicines in Canada. The goal of these negotiations is to
achieve “greater value for publicly funded drug programs and
patients.” If an agreement is reached, a LOI is signed by the
manufacturer and the pCPA, and each participating jurisdiction
will decide whether and when to fund the medicine through
its own public drug plan through a confidential product-listing
agreement with the manufacturer (Council of the Federation,
2014; Milliken et al., 2015). A successful pCPA negotiation
does not guarantee drug listing by all participating provinces
or simultaneous listings in multiple provinces. The public
system reimbursement decision pathway for new medicines is
summarized in Figure 1.
The drug plan managers in each province also decide which
beneficiaries of their drug plan will be covered for the medicines
listed on the formulary. Due to budgetary and other province-
specific considerations, each of the provinces may use slightly
different criteria to determine whether a medicine or indication
should be listed leading to differences in listing practices from
one province to another, such as the number of medicines
that are listed overall, the number of new medicines that are
added to the list each year, which indications are covered
for each medicine and for what clinical criteria, and how
much of the medicine’s cost will be paid by the province
(Wong and Jepson, 2011).
Since 2012, an early-to-market approval scheme, called
“pre-NOC HTA process” was introduced for both CDR and
pCODR regimes. Since March 2018, CDR submissions, like
pCODR submissions, can be made up to 6 months prior
to NOC (CADTH, 2018a). Since 2017, INESSS has also
created its own formal pre-NOC scheme consistent with
CADTH (informally available since 2016 for oncology products
only, and by recommendation of the Minister only), in
order to better align with the timing of pCPA negotiations
(INESSS, 2017).
Canadians who rely on public health payers to access
medicines must wait significantly longer compared to individuals
in major markets around the world (Millson et al., 2016), and
Canadians who rely on private plans (Rovere and Skinner, 2016).
There is a significant regulatory approval lag for some new
medicines in Canada vs. United States and major European
Union markets (Shajarizadeh and Hollis, 2015). Furthermore,
once regulatory approval is obtained, Canadians wait longer than
those in the United States and many major European markets
to obtain public reimbursement for new medicines (Millson
et al., 2016). Probable reasons for the larger delays include
the sequential, multi-layered review processes (as described
above) conducted before public drug plans decide whether
to provide access to innovative medicines. For example, the
time-to-listing of new medicines approved by Health Canada
from 2004 to 2013 by at least one public health plan by
January 2015 was substantially longer than for listing by
at least one private plan (on average 468 days compared
to 132 days, respectively). Furthermore, coverage for new
medicines by public plans is also more limited than by
private plans. Over the same period, only 50% (231 out
of 464) of new medicines approved by Health Canada in
2004–2013 were listed by one or more public plans, whereas
89% (413 out of 464) were covered by at least one private
plan by January 2015. Only 11 out of 231 publicly listed
medicines were listed faster by public plans than private plans
(Rovere and Skinner, 2016).
The aim of our research, therefore, was to develop and report
a comprehensive analysis of time-to-reimbursement by public
payers in Canada and to explore the contributing factors to total
delays in public reimbursement. Although private payers’ total
time-to-reimbursement was beyond the scope of this study, we
note that there is evidence that private payer product listing
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FIGURE 1 | A Simplified Overview of the Public System Reimbursement Decision Pathway for New Medicines.
agreements are generally completed within 6 months of starting
the negotiation (PDCI, 2015, 2016).
MATERIALS AND METHODS
Study Design
We conducted a review of the total time from NOC to public
reimbursement broken out into individual review processes for
the nine provincial jurisdictions participating in CADTH (NIHB,
the only federal drug plan with available listings data, is excluded
due to limited data points available since its entry into the pCPA
process in early 2016). We also conducted separate analyses for
certain metrics not related to HTA for Quebec because it is the
only province that does not participate in the pan-Canadian
CADTH processes; INESSS conducts HTAs independently. The
study design for this research followed the STROBE Initiative’s
recommendations for reporting observational studies (von Elm
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et al., 2014). The time period under review is from the beginning
of 2012 through to the end of December 2016.
Data Sources
Canadian Agency for Drugs and Technology in Health
reimbursement recommendations issued through the CDR and
pCODR process between 2012 and 2016 and available on
CADTH website were cross-referenced with the Health Canada
NOC database (Health Canada, 2017b) to confirm the NOC
date for all new product submissions and indications submitted
to CADTH. Information from the pCPA website was used to
identify the negotiation status and outcomes up to the end of
December 2016, and provincial plan websites including Quebec
were used to obtain provincial listing status and dates. Funding
information for cancer medicines was obtained from the pCODR
Provincial Funding Summary reports. All information up to June
2016 was collected by IQVIA. Information to the end of 2016 was
supplemented by the authors.
Information about the populations receiving public drug
plan benefits was collected from CIHI’s National Prescription
Drug Utilization Information System (NPDUIS) database upon
request for the nine provincial jurisdictions, and from the Health
Ministry’s annual report in the case of Quebec (RAMQ, 2017).
Data Analyses
The measure used in our analysis is the mean or average, being
careful to include volumes whenever applicable. No adjustment
is made for changing volumes since much of the processes are
standardized and not meant to be impacted by different volumes.
The primary analysis compared: (1) the number of medicine
indications listed; and (2) the time to listing in Quebec, the time-
to-first listing, and time-to-country-wide listing in the other nine
jurisdictions. Given that Canada does not have a universal public
drug plan covering every Canadian, the status of pan-Canadian
drug listings can be complex to understand and measure. Thus,
a measure unique to Canada of broad-based or near-universal
listing was developed to proxy consistent listing across the
country. We use the term “country-wide listing” to refer to this
measure. Country-wide listing was calculated based on a new
medicine or indication being listed in a number of public plans
that together cumulatively represent at least 80% of the Canadian
population receiving public plan benefits (excluding Quebec’s
public beneficiary population; as earlier quoted, representing
one/third of the Canadian population). For example, if a product
was listed in Ontario (that province representing 40% of the
public drug plan beneficiary population in the nation), in British
Colombia (representing another 30% of the population) and in
Manitoba (representing 10%), then the cumulative 80% would be
considered to have achieved country-wide listing. This approach
is consistent with previous approaches of comparing Canada’s
reimbursement timelines with other countries that have single
national drug coverage plans (Millson et al., 2016).
A medicine was considered ‘listed’ if it had either a full or
restricted listing status by December 2016 – the latter including
coverage under a special or exceptional access program on
the formulary of a provincial drug plan or cancer agency.
Time-to-listing was evaluated as the number of calendar days
from the date of market authorization (NOC) to the date of
public reimbursement (i.e., when the medicine or indication
was listed by a jurisdiction). In this way, time-to-listing is an
indicator of the time taken for public payers to review and
include new medicines in their formularies and, accordingly,
the time taken for Canadian patients to have access to them.
The dates of marketing authorization, of CADTH submission
and recommendation, as well as of public reimbursement were
available for the exact day, month, and year, whereas the dates of
pCPA negotiation start and end were only available for the month
and year, with the last day of the month being posted by pCPA
regardless of the actual day. As a result, pCPA timelines could be
±30 days. Timelines for individual review segment for the nine
jurisdictions (all provinces excepting Quebec) were calculated
separately, representing all relevant decision and action points by
manufacturers and reviewers – from regulatory approval to HTA
recommendations to pCPA negotiation outcomes and to public
listing decisions.
Due to the fact that there were a different number of products
for each review segment, there were two ways of calculating time
to listing depending on the analysis. The first was to start from
listed products only, and calculate the respective times for each
review segment for that basket of products – this is a more precise
and accurate measure of time to listing for the basket of products
that eventually received listing; however, it does not capture the
timelines of medicines that did not achieve public listing during
the period under review in this study. Thus, a second method
was employed to calculate the average time for each individual
review segment, separately, for the respective cohort of products
that went through a particular review process (e.g., average time
for all products that went through CADTH; average time for
all products that went through pCPA; etc.), and then adding
them together. Although this is not as precise of a picture for
the products that eventually obtain listing, we believe it is a just
representation of the duration of each individual review process
for the entire cohort of new medicines and indications that pass
through the review system, including those that ultimately may
not succeed at being listed.
Time to first provincial listing was evaluated as the number
of calendar days between when a NOC was issued and when the
medicine indication was listed by the first of any of the nine
CADTH-partner provinces. Time to country-wide listing was
taken as the unweighted time from NOC until listed in provinces
(excluding Quebec) cumulatively covering at least 80% of the
population receiving public drug plan benefits.
As a final step in the data analysis, a time series analysis of total
time to listing was performed, comparing 2013-2014 and 2015-
2016 timeframes. We also conducted a sub-analysis for oncology
products so as to generate information specific to listing decisions
in this particular field of medicine.
RESULTS
Sequential Process and Effect
Figure 2 provides a summary of the review outcomes and listing
decisions as of December 2016. Approximately 22% of products
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reviewed by CADTH were issued a negative recommendation,
and the remainder (78%) received a positive or conditional
recommendation. Almost all products reviewed and approved by
CADTH were selected by the pCPA for joint negotiation or for
individual provincial negotiation (10% were not – note that the
pCPA also opted to negotiate on a few products that received
a negative CADTH recommendation), and the large majority
of these were negotiated (8% were not). Among those products
having been negotiated to completion, most were listed in at least
one province plus a few which had received a negative CADTH
recommendation or not been successfully negotiated by pCPA.
Cumulatively, 33% of the 175 new medicines and indications
that were reviewed by CADTH by 2015 did not get listed in any
one province. Moreover, only 26% of new products/indications
reviewed by CADTH achieved country-wide listing by the end of
2016. These results indicate that the sequential process from NOC
to listing filters out a large portion of new medicines.
Sequential Time to Listing
The number of days from a product receiving marketing approval
(NOC) to it being listed in any one province (excluding Quebec),
by review agency, is shown in Figure 3. The average cumulative
time from NOC to listing was 1.7 years (602 days). Most of this
time was taken up by the HTA and pCPA processes – at 39%
and 45% of total cumulative review time, respectively. Average
provincial listing times are for products ranging from one to nine
provincial listings.
Public Reimbursement Timelines, Over
Time
Listing times are shown in Figure 4 for Quebec, first provincial
listing and country-wide listing among other provinces, for
products that achieved listing in 2013-2014 as compared to 2015-
2016. Our analysis indicates that Canadian public reimbursement
delays have lengthened in time from NOC to provincial listing
in Quebec (53% increase), to first provincial listing other than
Quebec (38% increase), and to country-wide listing excluding
Quebec (21% increase). Although there was a simultaneous
increase in the volume of products and indications (16%) for
our first provincial listing measure, no increase was observed in
Quebec nor for our country-wide listing measure.
Contribution to Timeline Before and Up
to the End of HTA vs. Post-HTA
Processes (Including pCPA and Public
Plan Decisions)
Figure 5 shows the time taken for review processes up to the
HTA decision (upstream) and post-HTA (downstream) for the
same products examined under time-to-first provincial listing in
Figure 4, above. Downstream times have increased from 2013-
2014 to 2015-2016 to a greater extent than upstream (44 vs.
33% increase in number of days) but the volume of products
listed has also increased. The volume increase may be related to
the CDR backlog experienced in 2013-2014, when CDR began
experiencing resourcing issues which delayed the start of many
reviews that manufacturers submitted in 2013 and 2014. This
pushed many listings that would have occurred in 2013-2014
to the 2015-2016 period. The backlog could also explain the
33% or 67-day increase in the time taken from NOC to HTA
recommendation for products listed in 2015-2016 vs. 2013-2014.
Post-HTA timelines increased by 44% or 73 days, and this can
likely be explained in part by slower pCPA negotiation start times
and negotiation durations in 2016 (Millson, 2017).
Oncology vs. Non-oncology Public
Reimbursement Timelines – Recent
Trends
From 2013-2014 to 2015-2016, oncology listing timelines have
increased in all three measures in Canada (Quebec, first
provincial listing and country-wide listing), with the largest
increase being observed in Quebec (76% or 285 days increase),
followed by country-wide listing (32% or 145 days increase)
(Figure 6). With respect to the time-to-first provincial listing,
despite the 26% increase in oncology-specific timelines, the time
taken to list oncology products still remains shorter than for
non-oncology products (by 143 days in 2015-2016). Oncology
timelines in 2015-2016 had surpassed non-oncology product
timelines in both Quebec and country-wide (oncology timelines
were already longer than non-oncology in Quebec in 2013-2014).
Moreover, whereas oncology listing timelines have increased,
the number of oncology products being listed have fallen – as
a result, one can presume that volumes are not related to the
increasing timelines observed for oncology products. On the
other hand, both timelines and the number of non-oncology
listings have increased, thus could be related, for example through
the CDR back-log as mentioned above. The decline in the number
of oncology listings could be the result of the longer timelines
to list oncology products, creating a backlog of products still
undergoing review.
Time to First Provincial Listing, NOC to
End of HTA vs. Post-HTA – Oncology vs.
Non-oncology
Supplementary Figure S1 shows the time to first provincial
listing for the same cohort of products presented in Figure 6
but in this case the timeframes for listing are separated into
the sequential processes upstream and downstream. For non-
oncology products, the source of overall increases in listing times
stem from both upstream (NOC to HTA recommendation) and
downstream (post-HTA) processes (34% increase in time each or
79 and 60 days, respectively). The increased timeline from NOC
to HTA recommendation is likely due to the CDR backlog as
mentioned above, whereas the post-HTA timeline increases are
likely due to slower pCPA negotiation start times and durations
mentioned earlier. For oncology products, however, the source
of increase is entirely the post-HTA timeframe (59% increase
in time, or 90 days). In contrast to that for non-oncology
products, the NOC to HTA recommendation timeline decreased
slightly – likely due to increased frequency and/or earlier pre-
NOC submissions (see next section). Moreover, the increase in
post-HTA timelines was greater for oncology products than for
non-oncology products (59% or 90 days vs. 34% or 60 days,
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FIGURE 2 | Number of products that have completed a CADTH HTA review (2012- December 2015), a pCPA negotiation, and achieved at least one provincial listing
or country-wide listing as of December 2016. Yes, passed the respective review step; Active, still under review on December 31, 2016; n/a, review not yet begun;
No, did not pass the respective review step; Inaccessible, not available as a reimbursed benefit to eligible beneficiaries in the plan(s) – reflects the filtering effect.
FIGURE 3 | Average number of cumulative and segmental days from NOC to at least one provincial listing, by review agency, 2012–2016 (∗excludes products with
artificial pCPA dates of completed negotiations published January 31, 2014). Average times to listing in Quebec are excluded. Note that the pCPA total time includes
time from when the CADTH recommendation is issued, to the start of a pCPA negotiation. pCPA times could be ±30 days, as negotiation start and end times are
published as the last day of every month.
respectively). These trends are observed despite a lower volume
of oncology products being listed in 2015-2016 vs. 2013-2014.
HTA Review Timelines for CDR, pCODR
and INESSS
Average review times for different HTA bodies are presented
in Figure 7 for the 2012 to 2016 period. The aforementioned
backlog for the CDR process can be observed starting in 2013
and peaking in 2014. This backlog was resolved after the relevant
agencies began to impose application fees (Health Canada,
2017a). Although in 2016 HTA reviews were generally meeting
the agencies’ own target timelines of 180 days, on average the
CDR exceeded its target timelines over the 2012–2016 period due
to the backlog in 2013–2015. Although INESSS was generally
in line with target CDR and pCODR timelines in 2014 and
2015, 2016 trends appear to indicate that review timelines are
lengthening. This may or may not be due to increasing volumes
of reviews processed in 2016.
Differences in Time From NOC to First
Provincial Reimbursement Between
Submissions Made Pre-NOC vs.
Post-NOC
Time to first provincial listing is shown in Figure 8 for products
with pre-NOC HTA submissions, and products with post-NOC
HTA submissions. On average, non-oncology products with pre-
NOC HTA submissions (CDR) are listed approximately 6 months
(190 days) earlier than those having submitted post-NOC.
Similarly, for oncology products, submissions (pCODR) made
pre-NOC are listed approximately 4 months (135 days) earlier
than products with submissions made post-NOC. Likewise,
non-oncology products with pre-NOC HTA submissions have
Frontiers in Pharmacology | www.frontiersin.org 7 March 2019 | Volume 10 | Article 196
fphar-10-00196 March 27, 2019 Time: 17:51 # 8
Salek et al. Factor Influencing Delays to New Medicines
FIGURE 4 | For all CADTH reviewed products, average number of days from NOC to: Quebec listing, first provincial listing in at least one province other than
Quebec, and country-wide listing excluding Quebec, where “n” denotes the number of listings in each respective period.
FIGURE 5 | Time to First Provincial Listing, in number of days, (all provinces, excluding Quebec), as segmented based on the following timelines: from NOC to HTA
submission; from NOC to HTA recommendation; and from HTA recommendation to listing (source: CADTH reviews, excluding resubmissions).
a 42% greater probability of achieving listing in at least one
province (excluding Quebec) as compared to those with post-
NOC HTA submissions, while oncology products with pre-NOC
HTA submissions experience a 17% greater probability of being
listed as compared to those with post-NOC HTA submissions.
Pre-NOC HTA Submission Trends for
CDR and pCODR – Frequency and
Timelines
Overall, oncology products are submitted on the basis of
parallel review processes (pre- and post-NOC submissions) more
often than non-oncology products. More than 60% of pCODR
submissions included in our study period were submitted pre-
NOC, compared to 40% of CDR submissions (Figure 9).
Although submissions were permitted 6 months ahead of the
expected NOC date for oncology products, in practice the actual
timelines for submissions was half of that (3 months before
NOC). Submissions for non-oncology products were permissible
3 months in advance of expected NOC, and on average applicants
submitted two-thirds of the way into this prescribed period.
INESSS did not have a pre-NOC submission process during
our study period.
Relative Time to First Provincial Listing
Between HTA Substitutions Made
Pre-NOC vs. Post-NOC – Trend Over
Time
Time to first provincial listing between 2013-2014 and 2015-
2016 are shown in Supplementary Figure S2, as presented in
terms of whether products had pre-NOC HTA submissions or
post-NOC HTA submissions. For products listed in 2013-2014,
non-oncology products with parallel HTA reviews were 75%
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FIGURE 6 | Public reimbursement timelines for oncology vs. non-oncology products, and number of items listed (n), 2013-2014 and 2015-2016.
FIGURE 7 | Health Technology Assessment review times for CDR, pCODR and INESSS and number of manufacturer submissions from 2012 to 2016. Data for
INESSS represents products with completed recommendations by INESSS that had Health Canada NOCs starting in January 2014. As a result, very few reviews in
2014 are captured (likely starting in October 2014).
faster (3.5 months) in achieving first provincial listing, while
oncology products were listed 78% faster (2 months) under the
same circumstances. However, by 2015-2016, the gap widened
significantly in time to achieve first provincial listing between
products with pre-NOC and post-NOC HTA submissions.
In 2015-2016, oncology products with pre-NOC HTA
submissions experienced a 28% increase (68 days) in time
to first provincial listing as compared to the 2013-2014
time period (despite a lower volume), while oncology
products reviewed post-NOC experienced a 115% increase
(359 days) in the time taken to achieve first provincial
listing in the 2015-2016 vs. 2013-2014 periods. As a
result, in 2015-2016, the gap has widened fourfold to
reach 358 days longer (12 months), for a product with
post-NOC HTA review, to reach first provincial listing,
compared to pre-NOC HTA.
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FIGURE 8 | Time to first provincial listing from NOC for products having pre- vs. post-NOC HTA submission, and % listing rates for pre- and post-NOC HTA
manufacturer submissions (products with CADTH recommendation to December 2015, time to first provincial listing to December 2016).
FIGURE 9 | (Top) Percentage of HTA submissions submitted pre- and post-NOC, 2012–2016 (CADTH only). (Bottom) HTA submission timelines with respect to
target/permissible timelines for pre-NOC filing, pCODR vs. CDR.
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Non-oncology products with pre-NOC HTA reviews
experienced a 25% increase (84 days) in time-to-listing in
2015-2016 compared to 2013-2014, while those undergoing
post-NOC HTA reviews saw a 50% increase (223 days) in time
to first provincial listing over the same time period. Accordingly,
in 2015-2016, the gap in time to first provincial listing increased
by more than twofold to reach 251 days longer (8.4 months) for
non-oncology products reviewed post-NOC vs pre-NOC.
Whereas oncology products with post-NOC HTA submissions
had shorter time to first provincial listing than non-oncology
products in 2013-2014 (129 days shorter), in 2015-2016 they
had slightly longer time to first provincial listing than non-
oncology products with post-NOC HTA submissions, and their
volume had dropped significantly, whereas that of non-oncology
products had increased.
DISCUSSION
Currently, although there are performance target timelines set for
Health Canada’s and CADTH’s reviews, there are no such targets
set for the following review steps including the pCPA process
i.e., how soon a negotiation is initiated and its duration, and
public plans’ decisions to list after negotiations are completed.
The pCPA process can take a few weeks to more than a year
in some cases (PCPA, 2017), and public plans can take as long
as they want to, given budget realities. The development of
a formal pCPA process provides an opportunity to introduce
target time frames while taking into account the need for both
timely decisions and sufficient time for manufacturers and public
drug plan administrators to negotiate efficiently. Similar target
timeframes have been developed to manage the review processes
in other jurisdictions for regulators, HTA agencies, and public
plans alike (European Union, 1988).
This study confirms that Canadian public reimbursement
delays have lengthened in time from NOC to listing, and that
post-HTA times are the biggest contributor to the increasing
delays. This is especially notable for oncology review timelines,
which in some cases, surpass non-oncology product timelines,
resulting in a decline in the number of oncology medicines
being listed. The CDR backlog that began in 2013 was resolved
starting in 2015 following the implementation of application fees
that must accompany submissions and in 2016 the HTA review
process was generally meeting its target timelines of 180 days. On
the other hand, recent evidence suggests that pCPA negotiation
timelines continued to be lengthy in 2017 compared to 2016
(Millson, 2017).
Parallel processes like pre-NOC submissions represent an
opportunity both in terms of time gained and probability of
listing. Over our entire study period, parallel processes, such as
those allowing for pre-NOC submissions, reduced timelines by
an average of 6 months to reach first provincial listing for non-
oncology products and by 4 months for oncology products, and
pre-NOC submissions had a 42% and 17% greater probability
of achieving listing in the respective cases of non-oncology
and oncology submissions. Also, note that pre-NOC submission
criteria at the beginning of our study period were more limited
for the CDR process compared to the pCODR process, likely
explaining the difference observed in frequency. The CDR pre-
NOC process was initially reserved for products granted Priority
Review by Health Canada. However, although manufacturers
utilize the parallel review process more frequently for oncology
vs. non-oncology products, pre-NOC HTA submissions were
still under-utilized in general terms. In particular, manufacturers
making submissions for oncology products tended to submit
within the final three of the 6 months available in advance of
the expected NOC date, while manufacturers of non-oncology
products tended to wait two out of the 3-month pre-NOC period
before submitting. It is unknown what impact, if any, the recent
process change by CDR to allow up to 6 months before NOC
(from 3 months only) to make a submission for non-oncology
products will have on accelerating the HTA submission timelines,
and ultimately, the overall time to list.
The advantage observed seems to have been mainly driven
from the widened gap observed in 2015-2016, which was not
the case in the earlier period. In 2013-2014, there was minimal
advantage of utilizing parallel reviews in terms of lessening
time to listing (an approximately 2-3-month reduction in time).
However, the gap widened in 2015-2016 between pre-NOC and
post-NOC HTA submissions resulting in a delay of 8 months
to a year for post-NOC submissions as compared to pre-NOC
submissions. This gap between pre- and post-NOC timelines
seems to indicate longer post-HTA timelines specifically for
products that undergo the standard, post-NOC HTA submission
process. Additionally, whereas there used to be an advantage
for oncology products submitted post-NOC vs. non-oncology
post-NOC, it appears that is no longer the case. Moreover, time
to first provincial listing has also increased for pre-NOC HTA
submissions, bringing into question the potential for parallel
reviews to reduce overall time to list.
Before the creation of the CDR process in 2002, each of the
Canadian provinces had their own review boards, but conducting
multiple reviews was a costly and an inefficient use of resources
(Spitz, 2013). Furthermore, not all provinces had the capacity to
conduct full HTAs. Although the creation of new incremental
and sequential processes, such as the CDR in 2002, pCODR in
2011, and the pCPA in 2010 to replace multiple and uneven
provincial negotiations, may have reduced the workload for the
provinces, the timeliness and effectiveness of the reimbursement
system have not improved in recent years.
This study found that the mean time was 273 days for pCPA
to start and complete negotiations of CADTH-reviewed products
between 2012 and 2015, with an additional 67 days to reach at
least one provincial listing (up to December 2016) (Figure 3).
This combined total of 340 days is very similar to findings from
a study by Milliken et al. (Milliken et al., 2015) that reported
mean times to list of 324 days in nine jurisdictions following
CDR or pCODR recommendation between September 2007 and
August 2010, i.e., before the establishment of the pCPA. They
also reported mean times to list of 279 days following CADTH
listing recommendation between September 2010 and August
2013 for products that completed a pCPA negotiation, i.e., after
pCPA was established. With a timeline of 340 days from our
study over the 2012–2016 period, this comparison reveals that the
timeline situation does not appear to have improved since the last
major study assessing the impact of pCPA on timelines – and in
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fact, appears to have worsened, since our study indicated an
increase of 44% in average post-HTA timelines to list in 2015-
2016 compared to 2013-2014. Accordingly, it can be concluded
that delays in patient access to new medicines have grown and
continue to grow.
Thanks to the availability of pre-NOC submissions,
manufacturers have succeeded in shortening the gap between
NOC and HTA submissions, and CADTH has made headway
in reducing the overall time to HTA recommendation from
NOC. However, total time to listing and patient access from
the time of regulatory approval continues to increase. The pCPA
process appears to be the main contributor to this increasing
time trend. More coordination and alignment between the HTA
and pCPA processes, and between pCPA and provinces, could
increase predictability in processes and timelines for industry.
Limitations
There are some limitations of this study that should be stated.
Analysis of the situation with regard to Quebec and individual
review components including INESSS was limited due to shorter
time period for data points collected. pCPA negotiation data is
incomplete. For example, it is lacking precise dates which could
add or subtract 30 days in pCPA calculations and is lacking
some negotiation start dates and LOI dates, as well as precise
indications negotiated, and participating jurisdictions including
lead jurisdictions. This study also did not consider timelines for
negative listing decisions by public plans due to limited and
inconsistent data in our study period for non-oncology products,
specifically. This study also did not include listing timelines for
medicines that fall outside of publicly available formularies, e.g.,
hospital non-oncology medicines, some rare disease medicines
paid for by other budgets (non-drug plan), etc.
CONCLUSION
A number of implications emerge from this study:
• The sequential review processes inherent to the Canadian
public reimbursement process make decisions time-
consuming and burdensome, resulting in long delays
for Canadians who rely on public plans for their
needed medicines.
• The lack of performance targets in some processes are
making the process less predictable both for industry as
well as for Canadian patients. Likewise, the lack of end
to end performance targets, e.g., from NOC to listing,
over and above individual agency accountability, could be
hampering the successes of individual agencies that are
meeting their own performance targets.
• The lack of coordination between different review
processes is increasing the delays in access to new
medicines for Canadian patients across the country.
• Parallel reviews applied across the entire reimbursement
process have the potential to improve time to listing
and overall efficiency, benefitting all stakeholders. Better
coordination amongst different review processes can be
explored using the HTA and regulatory parallel processes
as an example (pre-NOC). Opportunities exist to add
predictability and transparency in the process between
HTA and pCPA and between the pCPA and the provincial
listing processes.
• For example, having objective end to end performance
targets would further lend support to parallel reviews to
reduce overall timelines.
More research needs to be conducted to identify opportunities
to shorten overall time from NOC to provincial listing. The
source of delays being experienced during the pCPA process
and the extent to which increasing post-HTA timelines are due
to the conduct or policies of the provinces themselves needs
further exploration. Further study should look at opportunities
to take an integrated and system view perspective and build on
the strengths and successes of individual processes, to reduce
system-level inefficiencies and to explore parallel reviews and
other mechanisms to improve overall timelines for Canadian
patients’ access to new medicines.
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